Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-03-08
2011-03-08
Berch, Mark L (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S234200, C514S211150, C514S217060, C514S252160, C514S263210, C514S263200, C514S263220, C514S263240, C540S575000, C540S600000, C544S061000, C544S081000, C544S276000, C544S277000, C544S321000, C544S323000, C544S324000, C544S326000, C544S328000, C544S332000, C549S396000, C549S399000, C549S404000
Reexamination Certificate
active
07902187
ABSTRACT:
The present invention provides novel purinones and purines useful for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection. The compounds are of the general formulae I and II shown below, in which Q is selected from the group consisting of CX and nitrogen; and A is chosen from the group consisting of H, (C1-C6) alkyl, heteroaryl, and aryl:
REFERENCES:
patent: 4247556 (1981-01-01), von Bebenburg et al.
patent: 4813998 (1989-03-01), Van Lommen et al.
patent: 5493011 (1996-02-01), Jung et al.
patent: 5705625 (1998-01-01), Civin et al.
patent: 5916792 (1999-06-01), Civin et al.
patent: 6313129 (2001-11-01), Uckun et al.
patent: 6372740 (2002-04-01), Murata et al.
patent: 6432947 (2002-08-01), Arnaiz et al.
patent: 6452005 (2002-09-01), Uckun et al.
patent: 6506738 (2003-01-01), Yu et al.
patent: 6582357 (2003-06-01), Ouchi et al.
patent: 2004/0116435 (2004-06-01), Eriksson et al.
patent: 2004/0116449 (2004-06-01), Changelian
patent: 2004/0157739 (2004-08-01), Ahrens et al.
patent: 2005/0032725 (2005-02-01), Rao et al.
patent: 2007/0021443 (2007-01-01), Ohlmeyer et al.
patent: 2007/0253896 (2007-11-01), Le Brazidec et al.
patent: 2008/0085898 (2008-04-01), Lu et al.
patent: 2008/0085909 (2008-04-01), Roughton et al.
patent: 2008/0119496 (2008-05-01), Ohlmeyer et al.
patent: 2008/0207613 (2008-08-01), Styles et al.
patent: 2008/0214580 (2008-09-01), Neagu et al.
patent: 2008/0220256 (2008-09-01), Bhattacharya et al.
patent: 2008/0254029 (2008-10-01), Yanni et al.
patent: 2008/0287468 (2008-11-01), Ohlmeyer et al.
patent: 2009/0023723 (2009-01-01), Cole et al.
patent: 2009/0069289 (2009-03-01), Neagu et al.
patent: 2009/0281075 (2009-11-01), Roughton et al.
patent: 2238689 (1997-05-01), None
patent: 2841209 (1979-04-01), None
patent: 10 2005 042742 (2007-03-01), None
patent: 0 277 384 (1988-08-01), None
patent: 0 807 629 (1997-11-01), None
patent: 1043324 (2000-10-01), None
patent: 1221444 (2002-07-01), None
patent: 07075798 (1995-03-01), None
patent: 2004 217582 (2004-05-01), None
patent: 99/41248 (1999-08-01), None
patent: 00/12089 (2000-03-01), None
patent: 01/19828 (2001-03-01), None
patent: WO 02/055521 (2002-07-01), None
patent: 03/051277 (2003-06-01), None
patent: 2004/043386 (2004-05-01), None
patent: 2004/099204 (2004-11-01), None
patent: WO 2005/023761 (2005-03-01), None
patent: 2005/066156 (2005-07-01), None
patent: 2006/069080 (2006-06-01), None
patent: WO 2006/074985 (2006-07-01), None
patent: WO 2006/087538 (2006-08-01), None
patent: WO 2006/091737 (2006-08-01), None
patent: 2006/096270 (2006-09-01), None
patent: 2006/108103 (2006-10-01), None
patent: 2007/035873 (2006-10-01), None
patent: WO 2007/058990 (2007-05-01), None
patent: WO 2007/140222 (2007-12-01), None
patent: WO 2007/146712 (2007-12-01), None
patent: WO 2008/043019 (2008-04-01), None
patent: WO 2008/043031 (2008-04-01), None
patent: WO 2008/051493 (2008-05-01), None
patent: WO 2008/051494 (2008-05-01), None
patent: WO 2008/143674 (2008-11-01), None
patent: WO 2009/062059 (2009-05-01), None
Cetkovic-Cvrlje et al., “Dual Targeting of Burton's Tyrosine Kinase and Janus Kinase 3 with Rationally Designed Inhibitors Prevents Graft-Versus-Host Disease (GVHD),”British Journal of Haematology, vol. 126, pp. 821-827 (2004).
Cetkovic-Cvrlje et al., “Targeting Janus kinase 3 in the treatment of leukemia and inflammatory diseases,”Arch. Immunol. Ther. Exp., vol. 52, pp. 69-82 (2004.).
Changelian et al., “Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor,”Science, vol. 302, pp. 875-878 (2003).
O'Shea, J.J., “Cytokine signaling: new insights and new opportunities for therapeutic intervention?”,Arthristis Res., vol. 3(Suppl A): L018 (2001).
Ortmann et al., “Janus kinases and signal transducers and activators of transcription: their roles in cytokine signaling, development and immunoregulation,”Arthritis Res., , vol. 2, pp. 16-32 (2000).
Yamaoka et al., “The Janus kinases (Jaks),”Genome Biology, vol. 5:253, pp. 253.1-253.6 (2004).
Uckun et al., “Structure-based Design of Novel Anticancer Agents,”Current Cancer Drug Targets, vol. 1(1), pp. 59-71 (2001).
Kawahara et al., “Critical role of the interleukin 2 (IL-2) receptory-chain associated Jak3 in the IL-2-induced c-fosand c-myc, but notbcl-2, gene induction,”Proc. Natl. Acad. Sci., vol. 92, pp. 8724-8728 (1995).
O'Shea et al., “A New Modality for Immunosuppression: Targeting the Jak/Stat Pathway,”Nature Reviews, vol. 3, pp. 555-564 (2004).
Papageorgiou et al., “Is Jak3 a new drug target for immunomodulation-based therapies?”TRENDS in Pharmacological Sciences, vol. 25(11), pp. 558-562 (2004).
Lin et al., “Constitutive Activation of Jak3/Stat3 in Colon Carcinoma Tumors and Cell Lines”,American Journal of Pathology, vol. 167(4), pp. 969-980 (2005).
Dana et al, “Role of Immunity and Inflammation in Corneal and Ocular Surface Disease Associated with Dry Eye,”Lacrimal Gland, Tear Film and Dry Eye Syndromes 3, pp. 729-738 (2002).
Nagelhout et al., “Preservation of Tear Film Integrity and Inhibition of Corneal Injury by Dexamethasone in a Rabbit Model of Lacrimal Gland Inflammation-Induced Dry Eye,”Journal of Ocular Pharmacology and Therapeutics, vol. 21(2), pp. 139-148 (2005).
Pflugfelder, S., “Perspective Anti-inflammatory Therapy for Dry Eye,”American Journal of Ophthalmology, vol. 137(2), pp. 337-342 (2004).
Amin et al., “Inhibition of Jak3 induces apoptosis and decreases anaplastic lymphoma kinase activity in anaplastic large cell lymphoma,”Oncogene, vol. 22, pp. 5399-5407 (2003).
Harrington et al., “VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo,”Nature Medicine, vol. 10(3), pp. 262-267 (2004).
Jung et al., “Discovery of Novel and Potent Thiazoloquinazolines as Selective Aurora A and B Kinase,” American Chem Soc., pp. 1-16 (2005).
Frantz, S., “Playing Dirty”,Nature, vol. 437, pp. 942-943 (2005).
Martinez-Lostao et al., “Role of the STAT1 pathway in apoptosis induced by fludarabine and Jak kinase inhibitors in B-cell chronic lymphocytic leukemia,”Leuk Lymphoma, vol. 46(3), pp. 435-442 (2005), Abstract only (PMID: 15621835).
Lai et al., “Jak3 activation is significantly associated with ALK expression in anaplastic large cell lymphoma,”Human Pathology, vol. 36, pp. 939-944 (2005).
Pearson, H., “Designer transplant drug shows promise in monkeys,”News&Nature(2003).
Goldberg et. al., “Optimization of 2-Phenylaminoimidazo [4,5-h]isoquinolin-9-ones: Orally Active Inhibitors of Ick Kinase,”Journal of Medical Chem., vol. 46, pp. 1337-1349, 2003.
International Search Report from International Application No. PCT/US2006/012824.
International Search Report from International Application No. PCT/US2006/061004.
Beijersbergen van Henegouwen GM et al., Hydrolysis of RRR0alpha-tocopheryl acetate (vitamin # acetate) in the skin and its UV protecting activity (an in vivo study with the rat)J Photochem Photobiol, Jul. 29, 2005, vol. 1, pp. 45-51.
International Search Report from International Application No. PCT/US2007/080447.
International Search Report from International Application No. PCT/US2007/080464.
International Search Report and Written Opinion from International Application No. PCT/US2007/081232.
International Search Report and Written Opinion from International Application No. PCT/US2007/069530.
Hirota et all, “Synthesis and Biological Evaluation of 2,8-Disubstituted 9-Benzyladenines: Discovery of 8-Mercaptoadenines as Potent Interferon-Inducers,”Bioorganic&Medicinal Chemistry 11, 2003, pp. 2715-2722.
Written Opinion corresponding to PCT/US2007/080447.
Written Opinion corresponding to PCT/US2007/080464.
Written Opinion corresponding to PCT/US2006/012824.
Written Opinion corresponding to PCT/US200
Ansari Nasrin
Bohnstedt Adolph C.
Diller David
Kingsbury Celia
Neagu Irina
Berch Mark L
Sabnis Ram W.
Wyeth LLC
LandOfFree
6-substituted 2-(benzimidazolyl)purine and purinone... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 6-substituted 2-(benzimidazolyl)purine and purinone..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 6-substituted 2-(benzimidazolyl)purine and purinone... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2781524